People with asthma (PWA) generally are considered at higher risk from respiratory infections, as is seen annually with influenza. At the outset of the COVID-19 pandemic, PWA were widely assumed to be at increased risk from COVID-19. However, as data emerged throughout 2020, the association between asthma and COVID-19 appeared less clear

31 March 2021 The current evidence on the use of ivermectin to treat COVID-19 patients is inconclusive. Until more data is available, WHO recommends that the drug only be used within clinical trials. This recommendation, which applies to patients with COVID-19 of any disease severity, is now part of WHO’s guidelines on COVID-19 treatments. Ivermectin is a broad spectrum anti-parasitic agent, included in WHO essential medicines list for several parasitic diseases. It is used in the treatment of onchocerciasis (river blindness), strongyloidiasis and other diseases caused by soil transmitted helminthiasis. It is also used to treat scabies

Este documento de orientación está destinado a los médicos que atienden a pacientes con COVID-19 durante todas las fases de su enfermedad (es decir, desde el examen hasta el alta). Esta actualización se ha ampliado para satisfacer las necesidades de los médicos de primera línea y promueve un enfoque multidisciplinario para la atención de los pacientes con COVID-19, incluidos aquellos con enfermedades leves, moderadas, graves y críticas. Las siguientes secciones son completamente nuevas: la vía de atención de COVID-19, el tratamiento de las infecciones agudas y crónicas, el manejo de las manifestaciones neurológicas y mentales, las enfermedades no transmisibles, la rehabilitación, los cuidados paliativos, los principios éticos y la notificación de la muerte; mientras que los capítulos anteriores también se han ampliado considerablemente

doi: https://doi.org/10.1101/2020.11.30.20236570 Pre-Print Article

Slideset updated regularly to reflect the state of the COVID-19 pandemic and to include the latest data and guidance on best practices for diagnosis and prevention of transmission.

Slideset updated regularly to include the latest data and guidance on non-therapeutic and therapeutic treatments for COVID-19, including authorized and investigational agents.

based on information as at 28 February 2021 Rapid Policy Brief Series Series 14: COVID-19 and hypertension

Sur la base des informations disponibles au 28 février 2021 Rapid Policy Brief Series Series 14: COVID-19 and hypertension

— com base na informação disponível a 28 de Fevereiro de 2021 Rapid Policy Brief Series Series 14: COVID-19 and hypertension